2273 (2273) Fair Value & Analysis

Healthcare · Market cap HK$5.5B

2 2273 2273 · HK

PriceHK$27.96

Fair ValueHK$41.95

Upside+50.0%

Quality63/100

Watch 2273 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$31.59 – HK$52.28

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price +6.2% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$24.81 – HK$35.95 · fair‑value band HK$31.59 – HK$52.28 · the HK$27.96 price screens below the HK$41.95 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2273 (2273) currently trades at HK$27.96, while our model-based Fair Value estimate is HK$41.95 — implying the stock looks roughly 50.0% undervalued today. We read business quality at 63/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 2273 generated revenue of HK$3.2B at a net margin of 10.9%. Revenue grew 5.8% year over year. It earns a return on equity of 15.4%. The balance sheet holds a net cash position of HK$129M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$3.2B

Revenue growth (YoY) +5.8%

Net margin 10.9%

Return on equity 15.4%

Free cash flow HK$483M FY2025

P/E ratio 15.4

More key figures

Operating margin 14.1%

EPS (TTM) HK$0.6200

Dividend yield 3.6%

EPS growth (YoY) +5.9%

Net cash HK$129M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2273 reported revenue of HK$3.2B in FY2025 versus HK$1.4B in FY2021, a compound +24.0%/yr. Reported net income was HK$353M in FY2025.

Revenue +24.0%/yr

FY21 HK$1.4B

FY22 HK$1.6B

FY23 HK$2.3B

FY24 HK$3.0B

FY25 HK$3.2B

Net income

FY21 −HK$507M

FY22 HK$181M

FY23 HK$252M

FY24 HK$307M

FY25 HK$353M

Is 2273 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc H1CA34	R$95.75	R$123.65	+29%
Fresenius SE FSNUY	$11.30	$8.61	-24%
5225 5225	8.67 MYR	3.08 MYR	-64%
IHHHF IHHHF	$1.71	$0.7400	-57%
Tenet Healthcare Corporation THC	$162.06	$282.55	+74%
Rede D'Or São Luiz S.A RDOR3	R$32.76	R$30.33	-7%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2273 (2273) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$41.95 versus a price of HK$27.96 — about +50% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 2273?

Our model-based fair value for 2273 is HK$41.95 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$27.96.

What is the quality score of 2273?

2273 has a Quality Score of 63/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2273 (2273)?

2273 reported trailing-twelve-month revenue of about HK$3.2B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2273?

The net profit margin of 2273 is about 10.9%, meaning it keeps roughly 10.9% of revenue as net income. Based on the latest reported figures.

Does 2273 pay a dividend?

2273 currently shows a dividend yield of about 3.61% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.